Trial Profile
Antiangiogenic activity of metronomic therapy with capecitabine in metastatic solid tumors of gastrointestinal tract: a phase II study.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 16 Mar 2012
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary)
- Indications Gastrointestinal cancer
- Focus Biomarker; Therapeutic Use
- 15 Mar 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
- 02 Jun 2011 New trial record